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ABSTRACT
Introduction: Retrospective analyses of specific 
subgroups of patients from the database of the 
ACTION study have evaluated the effectiveness of 
a nifedipine gastrointestinal therapeutic system 
(GITS) on clinical outcomes. These subgroups 
included those patients receiving: 1) full 
“optimal” therapy at baseline; 2) full “optimal” 
therapy at baseline but excluding renin 
angiotensin system (RAS)-blocking drugs; 
3) treatment with nifedipine GITS who were 
not treated with RAS blockers versus those 
treated with RAS blockers but not nifedipine 
GITS. Methods: Analyses were performed on an 
intention-to-treat basis. Treatment groups were 
compared by log-rank test without adjustment 
for covariates. Hazard ratios with 95% confidence 




hazards models with treatment allocation 
as the only covariate. Results: 2461 patients 
randomized in ACTION were receiving optimal 
therapy (beta blockers, nitrates, aspirin, statins) 
excluding RAS blockers at baseline. There were 
reductions associated with nifedipine GITS 
compared with placebo in all prespecified 
endpoints but statistical significance was only 
achieved for debilitating stroke (48%; P<0.02) 
and coronary angiography (14%; P<0.05). 
These benefits were paralleled by a –4.1 and 
–2.8 mmHg difference between the groups for 
systolic and diastolic blood pressure, respectively. 
Patients randomized to nifedipine GITS but 
no RAS blockers (n=2966) when compared to 
those receiving RAS blockers but no nifedipine 
GITS (n=880) had highly statistically significant 
reductions in cardiovascular events (22%), new-
onset heart failure (53%), and debilitating stroke 
(45%). However, the groups differed in their 
baseline characteristics. Conclusion: Addition 
of nifedipine GITS to the treatment regimen 
of selected patient groups with symptomatic 
coronary artery disease results in a significant 
reduction of cardiovascular morbidity. While the 
interpretation of these subgroup analyses must 
obviously be cautious, there is a clear message 
relating to “best practice” treatment of angina, 
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which suggests that “reliance” on RAS blockade 
may be misplaced and greater attention should 
be directed towards control of blood pressure.
Keywords: ACE inhibitor; angina pectoris; 
angiotensin receptor blockers; blood pressure; 
calcium channel blockers; combination drug 
therapy; coronary artery disease; hypertension; 
nifedipine
INTRODUCTION
The European guidelines for the treatment 
of stable angina pectoris recommend that, in 
addition to risk factor modification, the focus 
should be upon improving prognosis and 
minimizing symptoms.1 The recommended 
algorithm for improving prognosis suggests that 
the regimen should include anti-thrombotic 
drugs (usually low-dose aspirin), lipid lowering 
with statins, angiotensin-converting enzyme 
(ACE) inhibitors, and beta-blockers. Where 
symptoms persist, the guidelines also suggest 
the use of (long-acting) calcium channel 
blockers (CCBs). These recommendations are, 
in part, founded on evidence-based medicine 
and a logical interpretation of the available 
data from randomized controlled trials. 
However, it should be recognized that much 
of the guidance is based upon “established 
practice” and benefit by way of improvement 
of symptoms. There is a relative paucity of 
definitive outcome trials and the available 
evidence is not wholly consistent. For example, 
although the HOPE study (Heart Outcomes 
Prevention Evaluation)2 demonstrated that 
there were significant and clinically relevant 
benefits with ACE inhibitor treatment (ramipril) 
in patients with stable coronary artery disease, 
the magnitude of the benefit in the EUROPA 
trial (EURopean trial On reduction of cardiac 
events with Perindopril in stable coronary 
Artery disease)3 was much smaller and there 
was no apparent benefit in the PEACE trial 
(Prevention of Events in ACE Inhibition) (with 
trandolapril).4 With respect to CCB treatment, 
ACTION (A Coronary disease Trial Investigating 
Outcome with Nifedipine gastrointestinal 
therapeutic system [GITS]) established that 
nifedipine (in its long-acting GITS formulation) 
can improve the prognosis of patients with 
chronic stable angina, particularly in those 
with concomitant hypertension.5,6
This further retrospective analysis of data 
derived from ACTION addresses practical 
treatment issues in patients with established 
stable coronary artery disease. With the ultimate 
aim of identifying optimal treatment strategies 
in this group of high-risk patients, the analysis 




The design, methods, and main results of 
the ACTION trial have been published in detail 
previously.5,7 In brief, patients with angina 
pectoris were randomized to receive either 
nifedipine GITS or matching placebo. In addition 
to angina, patients had to have either a history 
of myocardial infarction, proven angiographic 
coronary artery disease, or a positive exercise test 
or perfusion defect. The left ventricular ejection 
fraction had to be at least 40%. Selection 
criteria and definitions have been previously 
described in detail elsewhere.7 The starting dose 
of nifedipine GITS or placebo was 30 mg once 
daily, increasing to 60 mg once daily within 
6 weeks. These treatments were in addition to 
“best practice” cardiovascular therapy, with 
a follow-up period of 4 years. This further 
analysis has explored a number of aspects of the 
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effectiveness of different treatment options in 
patients with chronic stable angina.
Statistical Methods
This present analysis has focused on a 
number of composite endpoints that were 
predefined prior to the conduct of the ACTION 
trial. The endpoints included: the combined 
rate of death from any cause, myocardial 
infarction, refractory angina requiring 
coronary angiography, new overt heart failure 
requiring hospitalization, and peripheral 
revascularization (the ACTION primary 
endpoint for efficacy); the combined rate of 
death from any cause, myocardial infarction, 
and debilitating stroke (the ACTION primary 
endpoint for safety); any cardiovascular 
event (the ACTION primary endpoint for 
efficacy minus noncardiovascular death); any 
death, cardiovascular event, or procedure 
(the ACTION primary endpoint for efficacy 
plus coronary angiography, percutaneous 
coronary intervention, and coronary bypass 
surgery); and any vascular event or procedure 
(the ACTION primary endpoint for efficacy 
minus noncardiovascular death and new 
overt heart failure, plus percutaneous coronary 
intervention and coronary bypass surgery).
All analyses for composite outcomes and 
clinical events were performed on an intention-
to-treat basis. Deaths of unknown cause 
were considered as cardiovascular. Coronary 
angiography and percutaneous coronary 
intervention on the same day were counted 
only as percutaneous coronary intervention. 
Treatment groups were compared by the log-rank 
test without adjustment for covariates or interim 
analysis. Hazard ratios with 95% confidence 
intervals were obtained using Cox proportional 
hazards models with treatment allocation as the 
only covariate.
Thus, these present analyses have explored 
the outcome benefits attributable to the addition 
of nifedipine GITS in relation to the following 
different patterns of concurrent treatment:
Full “optimal” therapy at baseline (including 1. 
beta blockers, nitrates, aspirin, statins, and 
renin angiotensin system [RAS] blockers).
Full “optimal” therapy at baseline (as above) 2. 
but excluding RAS-blocking drugs.
Treatment with nifedipine GITS in 3. 
patients who were not treated with RAS 
blockers versus treatment with RAS 
blockers in patients who did not receive 
nifedipine GITS.
RESULTS
In brief, 7655 patients with angina pectoris 
were randomized to receive either nifedipine 
GITS (n=3825) or matching placebo (n=3840).
1)  Outcome in Patients Receiving “Optimal”  
 Therapy at Baseline
Evaluation of the database of 7665 patients 
randomized in ACTION revealed that at baseline 
only 464 were receiving beta blockers, nitrates, 
aspirin, statins, and RAS blockers—this being 
defined as full optimal therapy as recommended 
by the current European guidelines.1 Although 
the two groups (patients with angina pectoris 
receiving either nifedipine GITS or placebo) 
were well matched for baseline characteristics, 
the small number of patients precluded any 
meaningful statistical analysis due to the lack of 
statistical power. Nonetheless, the summarized 
outcome findings are presented in Table 1. Those 
patients randomized to nifedipine GITS attained 
lower blood pressure (BP) by the end of the trial 
(visit 18) than those randomized to placebo. 
The mean difference between the groups was 
–5.1 and –2.7 mmHg for systolic and diastolic 
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BP, respectively. All of the predefined outcomes 
favored nifedipine GITS with a 13% reduction in 
the primary outcome of efficacy, a 36% reduction 
in new-onset heart failure, and a 22% reduction 
in debilitating stroke (Table 1). None of the 
reductions achieved statistical significance.
2)  Outcome in Patients Receiving “Optimal” 
 Therapy Excluding RAS Blockers at Baseline
A total of 2461 patients randomized in ACTION 
were receiving optimal therapy excluding RAS 
blockers at baseline. The demographic and 
clinical features of the 1223 patients randomized 
to nifedipine GITS and 1238 to placebo are 
detailed in Table 2 along with the drug therapy 
at baseline. It is apparent from Table 2 that 
although these patients are a selected group 
from the randomized population they are well 
matched for the baseline characteristics with 
no statistically significant differences between 
the two groups. Four years after randomization 
(visit 18), the achieved BP in the nifedipine 
GITS and placebo group were 129.9/75.2 and 
134.4/78.0 mmHg, respectively. This represents 
a –4.1 and –2.8 mmHg difference in between the 
groups for SBP and DBP, respectively. Figure 1 
shows the effects of nifedipine GITS (relative 
to placebo) on predefined ACTION combined 
endpoints in patients receiving optimal therapy 
excluding RAS blockers at baseline. As evidenced 
by 95% confidence intervals that do not 
include “no effect” (hazard ratio=1), nifedipine 
significantly reduced debilitating stroke by 48% 
(P<0.02) and the coronary angiography by 14% 
(P<0.05). There also were reductions associated 
with nifedipine GITS in all the other prespecified 
endpoints, but these did not achieve statistical 
significance (Figure 1).
3)  Outcome in Patients Receiving Nifedipine 
 GITS but no RAS Blockers, Compared  
 to Those Receiving RAS Blockers but No  
 Nifedipine GITS
At total of 2966 patients in ACTION were 
randomized to nifedipine GITS but were not 
treated with RAS blockers, whilst 880 patients 





SBP/DBP at baseline (mmHg) 142.3/81.7 140.9/81.6
SBP/DBP at visit 18 (mmHg) 134.7/76.8 138.3/79.3
Change in SBP/DBP (mmHg) –7.4/–4.8 –2.3/–2.1
Hazard ratio Lower 95% CI Upper 95% CI
Primary efficacy 0.866 0.588 1.275
Primary safety 0.834 0.523 1.330
Any CV event 0.835 0.558 1.247
Death, any CV event, or revascularization 0.982 0.745 1.296
Any vascular event or revascularization 0.863 0.621 1.199
Heart failure 0.641 0.252 1.629
Debilitating stroke 0.782 0.248 2.465
Coronary angiography 0.978 0.695 1.377
Acute myocardial infarction 0.917 0.499 1.683
SBP/DBP=systolic/diastolic blood pressure; CV=cardiovascular.
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 Age, years (mean±SD) 62.9±9.2 62.2±9.3
 Men, % 76.1 77.6
Clinical features, %
 History of myocardial infarction (with coronary revascularization) 52.3 (25.8) 50.6 (25.0)
 Angiographic coronary artery disease, no MI (with coronary revascularization) 33.2 (20.6) 33.3 (19.7)
 Positive exercise or radionuclide test only 14.1 15.7
 No history of coronary artery disease 0.41 0.49
 Significant lesions on coronary angiogram 72.5 70.2
 Past use of calcium antagonists 21.8 21.0
 Anginal attacks 93.8 93.1
Risk factors, %
 Current smoker 18.4 18.6
 Total cholesterol ≥5.0 mmol/L 55.3 57.5
 Body mass index ≥30.0 kg/m2 23.5 24.3
 Diabetes mellitus 13.8 11.5
Cardiovascular variables, mean±SD
 Heart rate, b.p.m. 62.6±9.8 62.5±9.5
 SDB, mmHg 135.9±18.6 135.9±18.6
 DBP, mmHg 79.1±9.4 79.1±9.7
Antianginal drug, %
 Beta blocker 10 100
 Organic nitrate, as needed 74.9 73.4
 Organic nitrate, daily maintenance 46.6 46.2
 Other vasodilator 2.9 3.2
Lipid-lowering drug, %
 Statin 100 100
 Fibrate 1.9 2.1
 Other 1.4 1.9
 Any of the above 100 100
BP-lowering drug, %
 ACE inhibitor 0 0
 Angiotensin-II antagonist 0 0
 Diuretic 10.6 9.5
 Other 2.5 2.1
Other cardiovascular drug, %
 Acetylsalicylic acid 100 100
 Vitamin K antagonist 0.7 0.7
ACE=angiotensin-converting enzyme; MI=myocardial infarction; RAS=renin angiotensin system;  
SBP/DBP=systolic/diastolic blood pressure.
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were treated with RAS blockers but did not receive 
nifedipine GITS (placebo). The demographic and 
clinical features of these patients are detailed in 
Table 3 along with the drug therapy at baseline. 
It is apparent from Table 3 that these groups 
differed in their baseline characteristics. The 
use of RAS blockade was statistically more 
likely in patients with a previous myocardial 
infarction and diabetes mellitus. These patients 
also had markedly higher baseline BP at 
143.1±18.9/82.1±9.4 mmHg compared with 
135.7±18.1/79.2±9.3 in those patients receiving 
nifedipine GITS. During the course of the trial, 
BP was reduced in both groups such that 4 years 
after randomization (visit 18) the achieved BP 
in the nifedipine GITS (no RAS blockade) group 
was 129.7/75.4 mmHg and in the placebo group 
(with RAS blockade) was 139.0/79.5 mmHg. This 
represents a –1.7 and –1.2 mmHg difference in BP 
reduction during the course of the trial between 
the groups for SBP and DBP, respectively. Figure 2 
shows the comparison of the two groups for 
the predefined ACTION endpoints. There were 
reductions associated with nifedipine GITS in all 
the prespecified endpoints and these achieved 
statistical significance in all cases except the 
primary endpoint for safety and any vascular 
event or revascularization (Figure 2). There were 
highly statistically significant reductions in any 
cardiovascular events (22%), new-onset heart 
failure (53%), and debilitating stroke (45%).
DISCUSSION
Overall, the findings of these further analyses 
of the ACTION database suggest that there is 
considerable scope for improvement in the drug 
treatment of patients with stable coronary artery 
disease. The original aim of the ACTION trial was 
to establish the safety and efficacy of nifedipine 
GITS when added to “best practice treatment” 
of angina pectoris,5,7 but it is now apparent 
that “best practice” or “optimal” treatment 
reflected an algorithm for drug therapy derived 
from disparate levels of evidence with, in many 
Figure 1. Prespecified cardiovascular outcomes in 
patients receiving “optimal” therapy excluding RAS 
blockade at baseline. CV=cardiovascular; HR=hazard 
ratio; NS=nonsignificant.
Primary endpoint – ecacy 0.98 (0.82, 1.16) NS
HR (95% CI), P value
0.97 (0.78, 1.20) NS
0.98 (0.81, 1.17) NS
0.90 (0.80, 1.02) NS
0.87 (0.76, 1.01) NS
0.87 (0.53, 1.44) NS
0.52 (0.30, 0.91) 0.02
0.86 (0.74, 0.99) 0.05
Primary endpoint – safety 
Any CV event








Favors nifedipine Favors placebo
Figure 2. Prespecified cardiovascular outcomes 
in patients receiving nifedipine GITS with no 
RAS blockade and patients on placebo with 
RAS blockade. CV=cardiovascular; HR=hazard 
ratio; NS=nonsignificant.
Primary endpoint – ecacy 0.83 (0.71, 0.97) 0.018
0.90 (0.75, 1.09) NS
0.78 (0.66, 0.91) 0.003
0.82 (0.73, 0.92) 0.001
0.88 (0.76, 1.01) NS
0.47 (0.32, 0.69) 0.0001
0.55 (0.35, 0.86) 0.007
0.83 (0.72, 0.96) 0.013
Primary endpoint – safety 
Any CV event








Favors nifedipine Favors placebo
HR (95% CI), P value
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Table 3. Demographic and clinical features and drug therapy in patients receiving nifedipine GITS with no RAS blockade 






 Age, years (mean±SD) 63.4±9.4 63.7±9.2
 Men, % 80.6 76.5
Clinical features, %
 History of myocardial infarction (with coronary revascularization) 50.2 (23.8) 57.5 (29.4)
 Angiographic coronary artery disease, no MI (with coronary revascularization) 32.5 (20.8) 30.2 (17.8)
 Positive exercise or radionuclide test only 17.0 11.9
 No history of coronary artery disease 0.37 0.34
 Significant lesions on coronary angiogram 67.8 73.1
 Past use of calcium antagonists 21.9 21.0
 Anginal attacks 92.7 91.9
Risk factors, %
 Current smoker 18.7 14.2
 Total cholesterol ≥5.0 mmol/L 62.6 64.4
 Body mass index ≥30.0 kg/m2 20.6 27.0
 Diabetes mellitus 12.5% 23.0%
Cardiovascular variables, mean±SD
 Heart rate, b.p.m. 63.4±10.1 66.7±10.9
 SBP, mmHg 135.7±18.1 143.1±18.9
 DBP, mmHg 79.2±9.3 82.1±9.4
Antianginal drug, %
 Beta blocker 81. 79.7
 Organic nitrate, as needed 58.8 48.8
 Organic nitrate, daily maintenance 37.2 39.6
 Other vasodilator 3.7 5.7
Lipid-lowering drug, %
 Statin 63.3 63.1
 Fibrate 5.9 7.6
 Other 1.0 1.4
 Any of the above 68.0 69.2
BP-lowering drug, %
 ACE inhibitor 0 90.0
 Angiotensin-II antagonist 0 10.6
 Diuretic 7.9 23.5
 Other 2.8 2.5
Other cardiovascular drugs, %
 Acetylsalicylic acid 86.2 84.9
 Vitamin K antagonist 3.9 5.1
ACE=angiotensin-converting enzyme; GITS=gastrointestinal therapeutic system; MI=myocardial infarction;  
RAS=renin angiotensin system; SBP/DBP=systolic/diastolic blood pressure.
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instances, of proof of efficacy being based upon 
reducing symptoms rather than improving 
outcome.1 However, despite the relatively long-
established consensus on “optimal” treatment, 
only 6% of patients randomized in ACTION 
were receiving the full combination of beta 
blockers, nitrates, aspirin, statins, and drugs 
that block the RAS.7 Nevertheless, it might have 
been anticipated that the outcome benefits 
seen in ACTION following the addition of 
nifedipine GITS5,6 would predominantly have 
occurred in those patients receiving less than 
“optimal” therapy. In fact, the lowest rates 
for cardiovascular events were seen when 
treatment with nifedipine GITS was additional 
to “optimal” therapy (although the numbers in 
this retrospective analysis are too small for this 
to be considered definitive result). In addition 
to reducing cardiovascular morbidity, nifedipine 
treatment was associated with an expected 
further reduction in BP but it also should be 
borne in mind that nifedipine would likely also 
have provided additional symptomatic, anti-
anginal benefit in such patients.
In those patients whose “optimal” therapy 
did not contain a RAS-blocking drug at baseline, 
the assessment of cardiovascular outcomes 
again suggested that nifedipine GITS offered 
specific benefits: particularly a 48% reduction 
in debilitating stroke and a 14% reduction in 
coronary angiography. Although these groups 
were not independently randomized, they were 
found to be well matched at baseline with no 
statistical differences in their demographic 
features. The outcome benefits were paralleled 
by a greater BP reduction in the nifedipine GITS 
group, but nonetheless the selective benefit by 
way of stroke reduction is comparable with that 
achieved by ramipril in the HOPE trial.2 Thus, 
it is reasonable to conclude that significant 
outcome benefits can be achieved through the 
addition of nifedipine GITS to the treatment 
regimen of patients with stable coronary artery 
disease who are, for whatever reason, not 
receiving treatment with either an ACE inhibitor 
or an angiotensin receptor blocker (but who are 
otherwise receiving “optimal” therapy).
Combination treatment with nifedipine GITS 
and RAS blockade was the subject of previous 
retrospective analyses of the ACTION database 
attempting to evaluate whether RAS blockade 
was sufficient for cardioprotection or whether 
or not the addition of calcium CCBs with 
nifedipine GITS might offer additional benefit 
in the subgroup of patients who were already 
receiving “best practice,” “intensive” treatment 
including RAS blockade (ie, an ACE inhibitor 
and/or angiotensin receptor blocker).8 The 
results of this further analysis have identified 
that additional prognostic benefit was derived 
from the addition of nifedipine GITS. These 
benefits were related not only to those 
endpoints that have previously been shown to 
be predominantly associated with BP reduction, 
such as heart failure,9 but also to those that 
are BP-independent and can be attributed 
to the anti-ischemic properties of nifedipine 
(eg, coronary angiography). The overall trend 
was for greater reductions in all of the endpoints 
in the patients receiving the combination of 
RAS blockade and CCBs (nifedipine GITS) than 
for the overall ACTION population, despite a 
smaller differential BP reduction.8
The final further analysis in this present 
report was an assessment of the outcomes in 
those patients receiving nifedipine GITS but no 
RAS blockade compared with patients receiving 
placebo together with RAS blockade; this was 
specifically designed to assess the relative 
merits of CCBs compared to RAS blockade in 
patients with chronic stable angina. In this 
case, the analysis was confounded because 
there were significant discrepancies between 
the baseline characteristics of the two groups. 
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In particular, the group of patients receiving 
RAS blockade can be considered to be at greater 
cardiovascular risk on account of higher rates 
for previous myocardial infarction, diabetes, 
and a significantly higher baseline BP. Seeking to 
adjust for such discrepancies in a retrospective 
analysis is fraught with difficulties. It is thus not 
possible to deduce whether or not the significant 
improvement in outcome is solely associated 
with nifedipine GITS or whether it is a function 
of the higher cardiovascular risk in those not 
receiving nifedipine. Nevertheless, even if this 
analysis is considered to be “observational,” it is 
important to reflect that risk factor modulation 
in those patients receiving RAS blockade in 
the absence of nifedipine GITS is suboptimal 
particularly with respect to BP control.
The summarizing conclusion from all of this 
evidence is that the attainment of lower BP 
in these high-risk individuals is of paramount 
importance. Whilst this principle is widely 
acknowledged, it appears to be only slowly 
influencing the practice of clinical cardiologists 
and general practitioners. Since the publication 
of the HOPE trial2 in 2000, there has been a 
widespread perception that treatment with ACE 
inhibitor drugs—and ramipril in particular—is 
selectively beneficial in the treatment of patients 
with established coronary artery disease and 
that these benefits are not attributable to BP 
lowering alone. There is also a perception that 
the same arguments of selective benefit beyond 
BP control apply in patients who suffer not 
only from angina but also from diabetes. This 
position has been sustained despite the less-
convincing findings of the EUROPA3 and PEACE4 
trials. Overall, it appears that too much reliance 
is placed upon the selective benefits that may 
be offered by RAS blockade with insufficient 
attention being paid to the modulation of risk 
factors and the attainment of “tight BP control” 
in particular. Since the publication of HOPE,2 an 
important additional consideration is that the 
“standard” therapy for coronary artery disease 
has become more intensive. Thus, for example, 
some of the differences between the results of 
HOPE2 and those of PEACE4 may be explained by 
more intensive prior drug treatment and better 
risk factor control in the PEACE4 population. 
These baseline differences obviously would 
reduce the likelihood of a relatively well-
treated, low-risk population benefitting from 
additional ACE inhibitor treatment, as in the 
PEACE4 trial. The same interpretation can 
be applied to the muted effectiveness of the 
angiotensin receptor blocker, telmisartan, in 
the Telmisartan Randomised AssessmeNt Study 
in ACE iNtolerant subjects with cardiovascular 
Disease (TRANSCEND) study.10
CONCLUSION
In conclusion, the present analyses show 
that the addition of nifedipine GITS to 
the treatment regimen of selected patient 
groups with symptomatic coronary artery 
disease resulted in a significant reduction of 
cardiovascular morbidity. The interpretation of 
these analyses must obviously be cautious as it is 
based upon subgroup analyses which effectively 
break the randomization of the original study. 
Nonetheless, there is a clear message of practical 
clinical importance for the “best practice” 
treatment of angina: exclusive “reliance” on 
RAS blockade may be misplaced and greater 
attention should be directed towards control of 
BP (and particularly SBP) by means, if necessary, 
of combinations of BP-lowering drugs.
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